169 related articles for article (PubMed ID: 36309184)
1. Activation of the NLRP3 inflammasome by CCl
Vargas-Pozada EE; Ramos-Tovar E; Rodriguez-Callejas JD; Cardoso-Lezama I; Galindo-Gómez S; Gil-Becerril K; Vásquez-Garzón VR; Arellanes-Robledo J; Tsutsumi V; Villa-Treviño S; Muriel P
Ann Hepatol; 2023; 28(1):100780. PubMed ID: 36309184
[TBL] [Abstract][Full Text] [Related]
2. Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model.
Vargas-Pozada EE; Ramos-Tovar E; Rodriguez-Callejas JD; Cardoso-Lezama I; Galindo-Gómez S; Talamás-Lara D; Vásquez-Garzón VR; Arellanes-Robledo J; Tsutsumi V; Villa-Treviño S; Muriel P
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077357
[TBL] [Abstract][Full Text] [Related]
3. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
[TBL] [Abstract][Full Text] [Related]
4. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
5. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
[TBL] [Abstract][Full Text] [Related]
6. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
7. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
[TBL] [Abstract][Full Text] [Related]
8. Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH.
Li H; Cao Z; Wang L; Li J; Cheng X; Tang Y; Xing M; Yao P
J Nutr Biochem; 2023 Feb; 112():109217. PubMed ID: 36402251
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
[TBL] [Abstract][Full Text] [Related]
11. Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH.
Ioannou GN; Horn CL; Kothari V; Yeh MM; Shyu I; Lee SP; Savard CE
J Lipid Res; 2023 Feb; 64(2):100330. PubMed ID: 36641116
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway.
Cardoso-Lezama I; Fuentes-Figueroa MÁ; Ramos-Tovar E; Márquez-Quiroga LV; Ortiz-Fernández A; Vargas-Pozada EE; Arellanes-Robledo J; Tsutsumi V; Muriel P
Biochem Pharmacol; 2023 Oct; 216():115762. PubMed ID: 37604293
[TBL] [Abstract][Full Text] [Related]
14. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
[TBL] [Abstract][Full Text] [Related]
15. Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury.
Kim MY; Jeong B; Lee GS; Jeon H; Yang YM; Yang H; Han YH
Int Immunopharmacol; 2024 Feb; 128():111565. PubMed ID: 38262161
[TBL] [Abstract][Full Text] [Related]
16. Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.
Shi W; Xu G; Gao Y; Zhao J; Liu T; Zhao J; Yang H; Wei Z; Li H; Xu AL; Bai Z; Xiao X
J Transl Med; 2023 Oct; 21(1):700. PubMed ID: 37805545
[TBL] [Abstract][Full Text] [Related]
17. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
[TBL] [Abstract][Full Text] [Related]
18. Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy.
Zhang C; Tong Q; Liu K; Mao T; Song Y; Qu Y; Chen X; Qiu Z
Phytomedicine; 2024 Jul; 129():155703. PubMed ID: 38723527
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ.
Chen Y; He X; Yuan X; Hong J; Bhat O; Li G; Li PL; Guo J
Oxid Med Cell Longev; 2018; 2018():2901871. PubMed ID: 30140364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
